# Zimmer Biomet Holdings, Inc.

**ZBH**

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001136869

**C**

**middle fifth of 369 graded peers in healthcare**

rank 169 of 369; percentile 45.7; sampling error 2.5 points; lower is stronger


A B C D E

**C, the tortoise**




| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 43.0 |
| **Solvency** | C<br>percentile 46.9 |
| **Growth and financing** | C<br>percentile 50.6 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $23.1B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 10 of 14 |
| **Graded from** | filings received through Feb 20, 2026<br>264 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026 |
| **Last close** | $107.35<br>2026-11-10; market equity $20.3B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 20, 2026*

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic ("CMFT") products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 43.0** | | | | | | |
| Gross profitability | 24.8% | 32.3% | | 57.4 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |


*required facts have no common fiscal period end*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (4.5%) | (6.6%) | 63.7 | 800 | 2025-12-31 |
| Gross margin stability, five years | 0.7 pts | 2.8 pts | 7.9 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 46.9** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 3.96 | (0.35) | 21.8 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *required facts have no common fiscal period end* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 1.98x | 2.95x | 72.1 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 50.6** | | | | | |
| Revenue growth, three-year compound | 5.9% | 10.1% | 57.2 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | 8.0% | 11.0% | 54.3 | 95 | 2025-12-31 |
| Reinvestment rate | (59.4%) | 37.1% | 88.5 | 105 | 2025-12-31 |
| Asset growth, three years | 3.1% | 2.2% | 45.6 | 694 | 2025-12-31 |
| Net share issuance, one year | (1.7%) | 2.5% | 7.3 | 628 | 2026-02-10 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 164 | ImmunityBio, Inc. (IBRX) | 44.3 | C | short runway |
| 165 | Innoviva, Inc. (INVA) | 44.6 | C | |
| 166 | Avita Medical, Inc. (RCEL) | 44.8 | C | |
| 167 | Integer Holdings Corp. (ITGR) | 45.1 | C | |
| 168 | Pediatrix Medical Group, Inc. (MD) | 45.4 | C | |
| 169 | Zimmer Biomet Holdings, Inc. (ZBH) | 45.7 | C | |
| 170 | UroGen Pharma Ltd. (URGN) | 45.9 | C | |
| 171 | Orasure Technologies Inc. (OSUR) | 46.2 | C | |
| 172 | Anika Therapeutics, Inc. (ANIK) | 46.5 | C | fortress balance sheet |
| 173 | Enovis Corp. (ENOV) | 46.7 | C | |
| 174 | Lensar, Inc. (LNSR) | 47.0 | C | |

## What the price implies

*at the 2026-11-10 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (11.0%) | (1.9%) | 43 |
| Distance from 52-week high | (2.6%) | (28.5%) | 86 |
| EBIT to enterprise value | 5.3% | (1.6%) | 82 |
| Free cash flow yield | 7.3% | (1.0%) | 89 |
| Book value to price | 0.63 | 0.27 | 76 |
| Sales to price | 0.41 | 0.29 | 59 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | (14.0%) | 20.8% | 12 |
| Relative strength against the sector, log excess return | (0.28) | (0.19) | 43 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 6 of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $399.9M |
| Operating cash flow, four quarters | $1.9B |
| Months of runway | not finite |
| Days since last periodic filing | 7 (10-Q received Nov 4, 2026) |
| Median daily dollar volume, 63 sessions | $175.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $8.2B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.5B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 3 | assets | us-gaap:Assets | $23.1B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 4 | net income | us-gaap:NetIncomeLoss | $705.1M | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.7B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 6 | assets | us-gaap:Assets | $21.4B | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $7.7B | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 8 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.2B | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $7.4B | 2023-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 10 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.1B | 2023-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $6.9B | 2022-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 12 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.0B | 2022-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $6.8B | 2021-12-31 | 2024-02-23 | 10-K | 24-019353 |
| 14 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $2.0B | 2021-12-31 | 2024-02-23 | 10-K | 24-019353 |
| 15 | current assets | us-gaap:AssetsCurrent | $5.1B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $2.6B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $11.6B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $1.1B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 19 | book equity | us-gaap:StockholdersEquity | $12.7B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 20 | liabilities | us-gaap:Liabilities | $10.4B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $224.5M | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $1.5B | 2024-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $203.8M | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $1.6B | 2023-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $291.1M | 2023-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $1.4B | 2022-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $187.9M | 2022-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $1.1B | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 29 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $830.8M | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 30 | income tax | us-gaap:IncomeTaxExpenseBenefit | $125.7M | 2025-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 31 | current assets | us-gaap:AssetsCurrent | $4.7B | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 32 | current liabilities | us-gaap:LiabilitiesCurrent | $2.5B | 2024-12-31 | 2026-02-20 | 10-K | 26-059853 |
| 33 | assets | us-gaap:Assets | $21.5B | 2023-12-31 | 2025-02-25 | 10-K | 25-026604 |
| 34 | assets | us-gaap:Assets | $21.1B | 2022-12-31 | 2024-02-23 | 10-K | 24-019353 |
| 35 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 195,652,004 | 2026-02-10 | 2026-02-20 | 10-K | 26-059853 |
| 36 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 199,063,164 | 2025-02-14 | 2025-02-25 | 10-K | 25-026604 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.